Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study The Lancet DOI:https://doi.org/10.1016/S0140-6736(20)32009-2
For this cross-sectional study, in partnership with a central laboratory that receives samples from approximately 1300 dialysis facilities across the USA, we tested the remainder plasma of 28 503 randomly selected adult patients receiving dialysis in July, 2020.
Seroprevalence of SARS-CoV-2 was 8·0% (95% CI 7·7–8·4) in the sample, 8·3% (8·0–8·6) when standardised to the US dialysis population, and 9·3% (8·8–9·9) when standardised to the US adult population. When standardised to the US dialysis population, seroprevalence ranged from 3·5% (3·1–3·9) in the west to 27·2% (25·9–28·5) in the northeast. (0·4 [0·3–0·5]) when compared with a reduction of less than 5%.
During the first wave of the COVID-19 pandemic, fewer than 10% of the US adult population formed antibodies against SARS-CoV-2, and fewer than 10% of those with antibodies were diagnosed. Public health efforts to limit SARS-CoV-2 spread need to especially target racial and ethnic minority and densely populated communities.
MMWR: Changing Age Distribution of the COVID-19 Pandemic
The CDC released an MMWR describing the changing age distribution of COVID-19 infections in the United States from May-August 2020. During the first months of the pandemic, COVID-19 incidence was highest among older adults, but between June-August, COVID-19 incidence was highest in persons aged 20–29 years. This report provides preliminary evidence that younger adults contributed to community transmission of COVID-19 to older adults
